加载中
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
收盘时
US$12.29
−US$0.64 · -4.95%
盘后
US$12.29
US$0.00 · 0.00%
10月13日 16:31 ET
盘中时间采用ET。市场数据可能有所延迟。
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
日内区间
当前US$12.29
52周区间
当前US$12.29
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
40
偏贵
情绪
57
多空交织
风险
45
风险偏高
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
日内区间
当前US$12.29
52周区间
当前US$12.29
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 3347.8万 USD | 3937.7万 USD | 2368.3万 USD | 1983.4万 USD | 2298.4万 USD |
| 销售、一般及管理费用 | 1585万 USD | 1214.7万 USD | 1024万 USD | 1007.3万 USD | 949.2万 USD |
| 营业费用 | 4932.8万 USD | 5152.4万 USD | 3392.3万 USD | 2990.7万 USD | 3247.6万 USD |
| 利息收入 | 653.6万 USD | 360.2万 USD | 474.8万 USD | 174万 USD | 1万 USD |
| 利息支出 | — | 4000 USD | 39.1万 USD | 78万 USD | 120.2万 USD |
| 折旧和摊销 | 14.4万 USD | 14.7万 USD | 12.3万 USD | 4.3万 USD | 5万 USD |
| 营业利润 | −4932.8万 USD | −5152.4万 USD | −3392.3万 USD | −2990.7万 USD | −3247.6万 USD |
| 净利润 | −4275.9万 USD | −4791.1万 USD | −2906.5万 USD | −2915.2万 USD | −3394万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$29.67
上涨空间 141.42%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6739.32万0.00%2.3万亿 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM3610.64万0.05%787.4亿 USD0.19%US$276.71-0.43%
Vanguard Extended Market ETFVXF2269.39万0.02%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Growth ETFIWO1309.34万0.09%139.17亿 USD0.24%US$351.1-0.74%
Vanguard Russell 2000 ETFVTWO1022.62万0.06%180亿 USD0.06%US$111.77-0.45%
iShares Biotechnology ETFIBB971.2万0.09%108.2亿 USD0.44%US$200.02-2.08%
Schwab U.S. Small-Cap ETFSCHA817.18万0.04%217.13亿 USD0.03%US$32.56-0.31%
State Street SPDR S&P Pharmaceuticals ETFXPH735.71万1.57%4.69亿 USD0.35%US$62.10-2.98%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAState Street SPDR S&P Pharmaceuticals ETFXPHAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
